ScreenPoint Medical will showcase innovative new capabilities of its industry leading Breast AI, Transpara®, at the 2025 Society of Breast Imaging Symposium, April 24-27, 2025 (Booth #330).

The most clinically validated AI for breast cancer detection on the market, Transpara provides radiologists with a 'second pair' of eyes to help detect cancers earlier and reduce recall rates.

ScreenPoint will highlight its latest advancements, including Transpara 2.1, an update and improved breast cancer detection  d algorithm that further refines Transpara's industry-leading performance. This includes compatibility with options for breast density (BI-RADS like and volumetric) and temporal comparison with multiple prior exams.

This robust temporal comparison capability will be the first of its kind in the market, and will allow suspicious areas on a current study to be analyzed against up to 3 priors over 6 years. The Transpara 2.1 algorithm is both CE-marked and FDA cleared.

"We are excited about the significant improvement of Transpara performance when priors are used, especially when more priors with a longer time interval are included, which is in line with radiologists' experience. Our solution is designed for screening and diagnostic use to truly improve clinical workflow," said Professor Nico Karssemeijer, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical.

With 35+ peer-reviewed publications, Transpara is the only breast AI algorithm evaluated in large-scale real-world screening populations multiple times (including UCLA, Capital Region of Denmark, Lund University in Sweden, Norwegian Cancer Registry, Reina Sofia Hospital Cordoba). Results of the MASAI  trial, demonstrate that Transpara-assisted workflow increased cancer detection by 29 percent and resulted in a 44 percent reduction in the screen-reading workload for radiologists.